ENDPOINTS

FDA OKs new label expansions for Dupixent and Incyte's Monjuvi

Plus, news about Novartis' Mariana Oncology: FDA approves Dupixent in rare autoimmune disease: The approval is for bullous pemphigoid, a condition in which the immune system attacks ...

Jun 20, 2025 - 15:20
 0
FDA OKs new label expansions for Dupixent and Incyte's Monjuvi
Plus, news about Novartis' Mariana Oncology: FDA approves Dupixent in rare autoimmune disease: The approval is for bullous pemphigoid, a condition in which the immune system attacks ...
Read More

Tags:

Previous Article

Early-stage investor Syncona readjusts priorities due to bleak biotech market

Next Article

Many elite athletes live below the poverty line. Tax-deductible donations won't ...

Related Posts

HHS urges against reviving Chamber of Commerce’s IRA suit

HHS urges against reviving Chamber of Commerce’s IRA suit

Jun 11, 2025  0

FDA approves Moderna’s next-gen Covid vaccine

FDA approves Moderna’s next-gen Covid vaccine

May 31, 2025  0

Endpoints Livestream: Trump's 'most favored nation' plan to cut drug prices

Endpoints Livestream: Trump's 'most favored nation' pla...

May 13, 2025  0